| # | Title | Journal | Year | Citations |
|---|
| 1 | Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study | Transplantation and Cellular Therapy | 2021 | 125 |
| 2 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report | Transplantation and Cellular Therapy | 2021 | 72 |
| 3 | Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy | Transplantation and Cellular Therapy | 2021 | 65 |
| 4 | Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients | Transplantation and Cellular Therapy | 2021 | 63 |
| 5 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report | Transplantation and Cellular Therapy | 2021 | 62 |
| 6 | Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States | Transplantation and Cellular Therapy | 2022 | 61 |
| 7 | Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial | Transplantation and Cellular Therapy | 2021 | 52 |
| 8 | Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy | Transplantation and Cellular Therapy | 2021 | 45 |
| 9 | American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation | Transplantation and Cellular Therapy | 2021 | 45 |
| 10 | Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients | Transplantation and Cellular Therapy | 2021 | 42 |
| 11 | Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access | Transplantation and Cellular Therapy | 2022 | 40 |
| 12 | Enteral versus Parenteral Nutrition as Nutritional Support after Allogeneic Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-Analysis | Transplantation and Cellular Therapy | 2021 | 38 |
| 13 | Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration | Transplantation and Cellular Therapy | 2021 | 36 |
| 14 | Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas | Transplantation and Cellular Therapy | 2022 | 36 |
| 15 | Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome | Transplantation and Cellular Therapy | 2023 | 36 |
| 16 | Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation | Transplantation and Cellular Therapy | 2022 | 32 |
| 17 | Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage | Transplantation and Cellular Therapy | 2022 | 31 |
| 18 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report | Transplantation and Cellular Therapy | 2021 | 29 |
| 19 | Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis | Transplantation and Cellular Therapy | 2021 | 28 |
| 20 | Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies | Transplantation and Cellular Therapy | 2021 | 27 |
| 21 | Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis | Transplantation and Cellular Therapy | 2021 | 27 |
| 22 | Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients | Transplantation and Cellular Therapy | 2021 | 27 |
| 23 | Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients | Transplantation and Cellular Therapy | 2022 | 27 |
| 24 | Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research | Transplantation and Cellular Therapy | 2023 | 27 |
| 25 | The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic | Transplantation and Cellular Therapy | 2021 | 26 |
| 26 | CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas | Transplantation and Cellular Therapy | 2021 | 26 |
| 27 | Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant | Transplantation and Cellular Therapy | 2021 | 26 |
| 28 | American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation | Transplantation and Cellular Therapy | 2021 | 26 |
| 29 | Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes | Transplantation and Cellular Therapy | 2022 | 26 |
| 30 | Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis | Transplantation and Cellular Therapy | 2021 | 25 |
| 31 | State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses | Transplantation and Cellular Therapy | 2021 | 25 |
| 32 | The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy | Transplantation and Cellular Therapy | 2021 | 24 |
| 33 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report | Transplantation and Cellular Therapy | 2021 | 24 |
| 34 | Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies | Transplantation and Cellular Therapy | 2021 | 24 |
| 35 | American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients | Transplantation and Cellular Therapy | 2021 | 23 |
| 36 | Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission | Transplantation and Cellular Therapy | 2021 | 23 |
| 37 | Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia | Transplantation and Cellular Therapy | 2021 | 22 |
| 38 | Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation | Transplantation and Cellular Therapy | 2021 | 21 |
| 39 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report | Transplantation and Cellular Therapy | 2021 | 21 |
| 40 | Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | Transplantation and Cellular Therapy | 2022 | 21 |
| 41 | Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy | Transplantation and Cellular Therapy | 2022 | 21 |
| 42 | Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products | Transplantation and Cellular Therapy | 2021 | 20 |
| 43 | Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease | Transplantation and Cellular Therapy | 2021 | 20 |
| 44 | Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation | Transplantation and Cellular Therapy | 2021 | 20 |
| 45 | Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis | Transplantation and Cellular Therapy | 2021 | 20 |
| 46 | Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis | Transplantation and Cellular Therapy | 2021 | 20 |
| 47 | Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel | Transplantation and Cellular Therapy | 2022 | 20 |
| 48 | Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant | Transplantation and Cellular Therapy | 2022 | 20 |
| 49 | Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality | Transplantation and Cellular Therapy | 2022 | 20 |
| 50 | Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients | Transplantation and Cellular Therapy | 2021 | 18 |
